Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionMalignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.HER2-positive breast cancer is lost in translation: time for patient-centered research.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Is there a role for immunotherapy in HER2-positive breast cancer?
P2860
Q26752780-BCC1B5CB-92E8-4C2B-A20D-D506E21EFAB5Q33829405-52172841-07AC-477A-85B1-F7B5FE12CACEQ36653537-6466FB41-7CEA-45C8-B4C7-BC4DE20B5E60Q37362747-0C24924A-58CE-4A53-9662-B0ADBD6B4AFEQ38648765-00ECF7E1-B08A-45D3-8A71-86160FE02863Q38752466-A8F7C334-48FC-413C-9FA2-B0EEB96D1CE9Q38786102-D043CC98-74D8-466D-96A6-A6374C933DAEQ39767744-551F9F11-0028-4533-95EC-2754BFE40CEDQ41149668-23E1C223-3265-4383-944B-33E62C2B8AD1Q42497114-8E998E77-0DB6-41C6-AD78-2ED99F92F057Q47782850-9D1982A5-9D2B-44C8-9D14-C8E61207FE9BQ48205560-67BC79DD-3EF4-4261-8543-7E5EFA98D763Q50083199-E9BFF82F-F5A6-4411-8224-6DED74821E8AQ51016839-950A8E6A-A0E3-4A47-8F77-C26A5B0A9C81Q51663342-9ECA1D44-7043-4AAC-991F-906C65611A05Q54187441-E7F3001B-C272-45E5-B021-412FD8CADBBFQ54957080-030D7254-1D6D-4A76-B420-03AA6756C125Q55428234-7698F47A-C547-4AB5-B07F-0D38DFC8BF5DQ57107866-010253DB-5C99-4FDD-BBC7-EF4708E7DF7B
P2860
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@ast
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@en
type
label
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@ast
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@en
prefLabel
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@ast
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@en
P2093
P2860
P50
P1433
P1476
Prospective Biomarker Analysis ...... or HER2-Positive Breast Cancer
@en
P2093
Catherine Ellis
Giancarlo Bisagni
Guido Ficarra
Katia Cagossi
Rocco Crescenzo
Samanta Sarti
Silvio Bicciato
P2860
P304
P356
10.1634/THEONCOLOGIST.2015-0138
P50
P577
2015-08-05T00:00:00Z